Tiny study aims to Fine-Tune fungal drug dosing during plasma exchange
NCT ID NCT07532850
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will look at how the antifungal drug liposomal amphotericin B behaves in 10 critically ill patients with severe fungal infections who are also receiving plasma exchange therapy. The goal is to understand how plasma exchange changes drug levels in the body, which could help doctors give the right dose. It is a small, early-stage study focused on gathering information, not testing a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal amphotericin B
What this could lead to
If successful, this could help doctors personalize dosing of liposomal amphotericin B for patients on plasma exchange, improving treatment effectiveness.
What could go wrong
This is a very small, early-stage study with only 10 participants, so results may not apply broadly. It focuses on drug levels, not directly on curing the infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••